Incb053914

Melanoma

Incyte CorporationPhase 1Dormant

C

33/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 23/ 100
Competitive Position: 65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / Sponsor	Phase	Rating
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd.	Phase 3	BB
Cyclophosphamide Primmune Therapeutics, Inc.	Phase 4	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Epirubicin Primmune Therapeutics, Inc.	Phase 4	BB
Pembrolizumab Biocon Biologics UK PLC	Phase 4	BB

View all 50 →

Same molecule, other indications

Incb053914 is also rated in:

Advanced MalignanciesDormant

CC

Indicative ·

45 / 100

neoplasmDormant

C

Indicative ·

39 / 100

relapsed/refractory diffuse large B-cell lymphomaDormant

C

Indicative ·

38 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.